Effect of intravenous alteplase on post-stroke depression in the WAKE UP trial.
DWI
MRI
WAKE-UP
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
revised:
20
02
2021
received:
14
01
2021
accepted:
22
02
2021
pubmed:
4
3
2021
medline:
13
8
2021
entrez:
3
3
2021
Statut:
ppublish
Résumé
The aim was to study the effect of intravenous alteplase on the development of post-stroke depression (PSD) in acute stroke patients, and to identify predictors of PSD. This post hoc analysis included patients with unknown onset stroke randomized to treatment with alteplase or placebo in the WAKE-UP trial (ClinicalTrials.gov number, NCT01525290), in whom a composite end-point of PSD was defined as a Beck Depression Inventory ≥10, medication with an antidepressant, or depression recorded as an adverse event. Multiple logistic regression was used to identify predictors of PSD at 90 days. Structural equation modelling was applied to assess the indirect effect of thrombolysis on PSD mediated by the modified Rankin Scale. Information on the composite end-point was available for 438 of 503 randomized patients. PSD was present in 96 of 224 (42.9%) patients in the alteplase group and 115 of 214 (53.7%) in the placebo group (odds ratio 0.63; 95% confidence interval 0.43-0.94; p = 0.022; adjusted for age and National Institutes of Health Stroke Scale at baseline). Prognostic factors associated with PSD included baseline medication with antidepressants, higher lesion volume, history of depression and assignment to placebo. While 65% of the effect of thrombolysis on PSD were caused directly, 35% were mediated by an improvement of the mRS. Treatment with alteplase in patients with acute stroke resulted in lower rates of depression at 90 days, which were only partially explained by reduced functional disability. Predictors of PSD including history and clinical characteristics may help in identifying patients at risk of PSD.
Sections du résumé
BACKGROUND AND PURPOSE
The aim was to study the effect of intravenous alteplase on the development of post-stroke depression (PSD) in acute stroke patients, and to identify predictors of PSD.
METHODS
This post hoc analysis included patients with unknown onset stroke randomized to treatment with alteplase or placebo in the WAKE-UP trial (ClinicalTrials.gov number, NCT01525290), in whom a composite end-point of PSD was defined as a Beck Depression Inventory ≥10, medication with an antidepressant, or depression recorded as an adverse event. Multiple logistic regression was used to identify predictors of PSD at 90 days. Structural equation modelling was applied to assess the indirect effect of thrombolysis on PSD mediated by the modified Rankin Scale.
RESULTS
Information on the composite end-point was available for 438 of 503 randomized patients. PSD was present in 96 of 224 (42.9%) patients in the alteplase group and 115 of 214 (53.7%) in the placebo group (odds ratio 0.63; 95% confidence interval 0.43-0.94; p = 0.022; adjusted for age and National Institutes of Health Stroke Scale at baseline). Prognostic factors associated with PSD included baseline medication with antidepressants, higher lesion volume, history of depression and assignment to placebo. While 65% of the effect of thrombolysis on PSD were caused directly, 35% were mediated by an improvement of the mRS.
CONCLUSIONS
Treatment with alteplase in patients with acute stroke resulted in lower rates of depression at 90 days, which were only partially explained by reduced functional disability. Predictors of PSD including history and clinical characteristics may help in identifying patients at risk of PSD.
Substances chimiques
Fibrinolytic Agents
0
Tissue Plasminogen Activator
EC 3.4.21.68
Banques de données
ClinicalTrials.gov
['NCT01525290']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2017-2025Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2021 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
Références
Towfighi A, Ovbiagele B, El Husseini N, et al. Poststroke depression: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2017;48(2):e30-e43.
Shi Y, Xiang Y, Yang Y, Zhang N, Wang S, Ungvari GS, et al. Depression after minor stroke: prevalence and predictors. J Psychosom Res. 2015;79(2):143-147. https://doi.org/10.1016/j.jpsychores.2015.03.012
Schöttke H, Giabbiconi CM. Post-stroke depression and post-stroke anxiety: prevalence and predictors. Int Psychogeriatrics. 2015;27(11):1805-1812.
Meng G, Ma X, Li L, et al. Predictors of early-onset post-ischemic stroke depression: a cross-sectional study. BMC Neurol. 2017;17(1):199.
Parikh RM, Robinson RG, Lipsey JR, Starkstein SE, Fedoroff JP, Price TR. The impact of poststroke depression on recovery in activities of daily living over a 2-year follow-up. Arch Neurol. 1990;47(7):785-789.Available from: http://archneur.jamanetwork.com/article.aspx?articleid=590221
Mak KK, Kong WY, Mak A, Sharma VK, Ho RCM. Polymorphisms of the serotonin transporter gene and post-stroke depression: a meta-analysis. J Neurol Neurosurg Psychiatry. 2013;84(3):322-328.
Grabowska-Fudala B, Jaracz K, Górna K, Miechowicz I, Wojtasz I, Jaracz J, et al. Depressive symptoms in stroke patients treated and non-treated with intravenous thrombolytic therapy: a 1-year follow-up study. J Neurol. 2018;265(8):1891-1899.Available from: http://www.ncbi.nlm.nih.gov/pubmed/29916129
Ilut S, Stan A, Blesneag A, Vacaras V, Vesa S, Fodoreanu L. Factors that influence the severity of post-stroke depression. J Med Life. 2017;10(3):167-171.Available from http://www.ncbi.nlm.nih.gov/pubmed/29075345%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC5652262
Mitchell AJ, Sheth B, Gill J, et al. Prevalence and predictors of post-stroke mood disorders: a meta-analysis and meta-regression of depression, anxiety and adjustment disorder. Gen Hosp Psychiatry. 2017;47:48-60.Available from: https://www.sciencedirect.com/science/article/pii/S0163834317301433?via%3Dihub
Lee E-J, Kim JS, Chang D-I, et al. Differences in therapeutic responses and factors affecting post-stroke depression at a later stage according to baseline depression. J Stroke. 2018;20(2):258-267. https://doi.org/10.5853/jos.2017.02712
Lees KR, Emberson J, Blackwell L, et al. Effects of alteplase for acute stroke on the distribution of functional outcomes: a pooled analysis of 9 trials. Stroke. 2016;47(9):2373-2379.
Sandercock P. Effect of thrombolysis with alteplase within 6 h of acute ischaemic stroke on long-term outcomes (the Third International Stroke Trial [IST-3]): 18-month follow-up of a randomised controlled trial. Lancet Neurol. 2013;12(8):768-776. https://doi.org/10.1016/S1474-4422(13)70130-3
Schwab-Malek S, Vatankhah B, Bogdahn U, Horn M, Audebert HJ. Depressive symptoms and quality of life after thrombolysis in stroke: the TEMPiS study. J Neurol. 2010;257(11):1848-1854.
Thomalla G, Simonsen CZ, Boutitie F, Andersen G, Berthezene Y, Cheng B, et al. MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med. 2018;379(7):611-622. https://doi.org/10.1056/NEJMoa1804355
Aben I, Verhey F, Lousberg R, Lodder J, Honig A. Validity of the Beck Depression Inventory, Hospital Anxiety and Depression Scale, SCL-90, and Hamilton Depression Rating Scale as screening instruments for depression in stroke patients. Psychosomatics. 2002;43(5):386-393.Available from http://linkinghub.elsevier.com/retrieve/pii/S0033318202703666
Berg A, Lönnqvist J, Palomäki H, Kaste M. Assessment of depression after stroke: a comparison of different screening instruments. Stroke. 2009;40(2):523-529.
Hackett ML, Yapa C, Parag V, Anderson CS. Frequency of depression after stroke: a systematic review of observational studies. Stroke. 2005;36(6):1330-1340.
Imai K, Keele L, Tingley D. A general approach to causal mediation analysis. Psychol Methods. 2010;15(4):309-334.Available from http://www.ncbi.nlm.nih.gov/pubmed/20954780
Imai K, Keele L, Tingley D, Yamamoto T. Unpacking the black box of causality: learning about causal mechanisms from experimental and observational studies. Am Polit Sci Rev. 2011;105(4):765-789.
Emsley R, Liu H. PARAMED: Stata module to perform causal mediation analysis using parametric regression models. Stat Softw Components S457581. 2013.
Schmid AA, Kroenke K, Hendrie HC. Poststroke depression and treatment effects on functional outcomes. Neurology. 2011;76:1000-1005.
Pohjasvaara T, Leppavuori A, Siira I, Vataja R, Kaste M, Erkinjuntti T. Frequency and clinical determinants of poststroke depression. Stroke. 1998;29(11):2311-2317.Available from http://stroke.ahajournals.org/content/29/11/2311.abstract
Wei C, Zhang F, Chen L, Ma X, Zhang N, Hao J. Factors associated with post-stroke depression and fatigue: lesion location and coping styles. J Neurol. 2016;263(2):269-276.
Vataja R, Leppävuori A, Pohjasvaara T, Mäntylä R, Aronen HJ, Salonen O, et al. Poststroke depression and lesion location revisited. J Neuropsychiatry Clin Neurosci. 2004;16(2):156-162. https://doi.org/10.1176/appi.neuropsych.16.2.156
de Weerd L, Luijckx GJR, Groenier KH, van der Meer K. Quality of life of elderly ischaemic stroke patients one year after thrombolytic therapy. A comparison between patients with and without thrombolytic therapy. BMC Neurol. 2012;12(1):1.
Karakus K, Kunt R, Memis CO, et al. The factors related to early-onset depression after first stroke. Psychogeriatrics. 2017;17(6):414-422.Available from http://www.ncbi.nlm.nih.gov/pubmed/28387015
De Ryck A, Fransen E, Brouns R, Geurden M, Peij D, Mariën P, et al. Poststroke depression and its multifactorial nature: results from a prospective longitudinal study. J Neurol Sci. 2014;347(1-2):159-166. https://doi.org/10.1016/j.jns.2014.09.038
Katzan IL, Thompson NR, Uchino K, Lapin B. The most affected health domains after ischemic stroke. Neurology. 2018;90(16):E1364-E1371.
Reeves M, Lisabeth L, Williams L, et al. Patient-reported outcome measures (PROMs) for acute stroke: rationale, methods and future directions. Stroke. 2018;49(6):1549-1556.
Ma H, Campbell BCV, Parsons MW, et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med. 2019;380(19):1795-1803.
Shi Y, Xiang Y, Yang Y, Zhang N, Wang S, Ungvari GS, et al. Depression after minor stroke: prevalence and predictors. J Psychosom Res. 2015;79(2):143-147.Available from https://linkinghub.elsevier.com/retrieve/pii/S0022399915000860
Sharpe M, Hawton K, Seagroatt V, et al. Depressive disorders in long-term survivors of stroke. Associations with demographic and social factors, functional status, and brain lesion volume. Br J Psychiatry. 1994;164(3):380-386. https://doi.org/10.1192/bjp.164.3.380
Vojtikiv-Samoilovska D, Arsovska A. Prevalence and predictors of depression after stroke-results from a prospective study. Open Access Maced J Med Sci. 2018;6(5):824-828.
Salinas J, Beiser A, Himali JJ, Rosand J, Seshadri S, Dunn EC. Factors associated with new-onset depression after stroke. J Neuropsychiatry Clin Neurosci. 2016;28(4):286-291. https://doi.org/10.1176/appi.neuropsych.15110388
Chollet F, Tardy J, Albucher J-F. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011;10(2):123-130.